aluates Reports

$ 0.0

Automative

Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Research Report 2024

Published Date: April 2024

Report Code: QYRE-Auto-27S13641

Global Castration Resistant Prostate Cancer CRPC HRPCA Therapeutics Market Research Report 2023

BUY CHAPTERS

Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Research Report 2024

Code: QYRE-Auto-27S13641

Report

April 2024

Pages:76

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size

The global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market was valued at US$ 7633.6 million in 2023 and is anticipated to reach US$ 11190 million by 2030, witnessing a CAGR of 5.2% during the forecast period 2024-2030.

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.

Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics.

Report Scope

The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Report

Report Metric	Details
Report Name	Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market
Accounted market size in 2023	US$ 7633.6 million
Forecasted market size in 2030	US$ 11190 million
CAGR	5.2%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Oral Therapy Injectable Therapy
Segment by Application	Hospitals & Clinics Home Settings Ambulatory Surgical Centers (ASCs)
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market growing?

Ans: The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market witnessing a CAGR of 5.2% during the forecast period 2024-2030.

What is the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market size in 2030?

Ans: The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market size in 2030 will be US$ 11190 million.

Who are the main players in the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market report?

Ans: The main players in the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market are Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG

What are the Application segmentation covered in the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market report?

Ans: The Applications covered in the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market report are Hospitals & Clinics, Home Settings, Ambulatory Surgical Centers (ASCs)

What are the Type segmentation covered in the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market report?

Ans: The Types covered in the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market report are Oral Therapy, Injectable Therapy

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Oral Therapy

1.2.3 Injectable Therapy

1.3 Market by Application

1.3.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospitals & Clinics

1.3.3 Home Settings

1.3.4 Ambulatory Surgical Centers (ASCs)

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Perspective (2019-2030)

2.2 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Growth Trends by Region

2.2.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Historic Market Size by Region (2019-2024)

2.2.3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Region (2025-2030)

2.3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Dynamics

2.3.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Industry Trends

2.3.2 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Drivers

2.3.3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Challenges

2.3.4 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players by Revenue

3.1.1 Global Top Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players by Revenue (2019-2024)

3.1.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Players (2019-2024)

3.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue

3.4 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Concentration Ratio

3.4.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in 2023

3.5 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Key Players Head office and Area Served

3.6 Key Players Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Solution and Service

3.7 Date of Enter into Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Breakdown Data by Type

4.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Historic Market Size by Type (2019-2024)

4.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Type (2025-2030)

5 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Breakdown Data by Application

5.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Historic Market Size by Application (2019-2024)

5.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2019-2030)

6.2 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024)

6.4 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2019-2030)

7.2 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024)

7.4 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2019-2030)

8.2 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2019-2024)

8.4 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2019-2030)

9.2 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024)

9.4 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2019-2030)

10.2 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024)

10.4 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Astellas Inc.

11.1.1 Astellas Inc. Company Detail

11.1.2 Astellas Inc. Business Overview

11.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Introduction

11.1.4 Astellas Inc. Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)

11.1.5 Astellas Inc. Recent Development

11.2 Johnson & Johnson

11.2.1 Johnson & Johnson Company Detail

11.2.2 Johnson & Johnson Business Overview

11.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Introduction

11.2.4 Johnson & Johnson Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)

11.2.5 Johnson & Johnson Recent Development

11.3 Sanofi S.A

11.3.1 Sanofi S.A Company Detail

11.3.2 Sanofi S.A Business Overview

11.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Introduction

11.3.4 Sanofi S.A Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)

11.3.5 Sanofi S.A Recent Development

11.4 Dendreon Corporation

11.4.1 Dendreon Corporation Company Detail

11.4.2 Dendreon Corporation Business Overview

11.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Introduction

11.4.4 Dendreon Corporation Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)

11.4.5 Dendreon Corporation Recent Development

11.5 Bayer AG

11.5.1 Bayer AG Company Detail

11.5.2 Bayer AG Business Overview

11.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Introduction

11.5.4 Bayer AG Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)

11.5.5 Bayer AG Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

List of Tables

Table 1. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Oral Therapy

Table 3. Key Players of Injectable Therapy

Table 4. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Region (2019-2024)

Table 8. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Region (2025-2030)

Table 10. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Trends

Table 11. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Drivers

Table 12. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Challenges

Table 13. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Restraints

Table 14. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Players (2019-2024)

Table 16. Global Top Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics as of 2023)

Table 17. Ranking of Global Top Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Solution and Service

Table 21. Date of Enter into Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Type (2019-2024)

Table 25. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Type (2025-2030)

Table 27. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Application (2019-2024)

Table 29. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Application (2025-2030)

Table 31. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 46. Astellas Inc. Company Detail

Table 47. Astellas Inc. Business Overview

Table 48. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product

Table 49. Astellas Inc. Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024) & (US$ Million)

Table 50. Astellas Inc. Recent Development

Table 51. Johnson & Johnson Company Detail

Table 52. Johnson & Johnson Business Overview

Table 53. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product

Table 54. Johnson & Johnson Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024) & (US$ Million)

Table 55. Johnson & Johnson Recent Development

Table 56. Sanofi S.A Company Detail

Table 57. Sanofi S.A Business Overview

Table 58. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product

Table 59. Sanofi S.A Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024) & (US$ Million)

Table 60. Sanofi S.A Recent Development

Table 61. Dendreon Corporation Company Detail

Table 62. Dendreon Corporation Business Overview

Table 63. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product

Table 64. Dendreon Corporation Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024) & (US$ Million)

Table 65. Dendreon Corporation Recent Development

Table 66. Bayer AG Company Detail

Table 67. Bayer AG Business Overview

Table 68. Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product

Table 69. Bayer AG Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024) & (US$ Million)

Table 70. Bayer AG Recent Development

Table 71. Research Programs/Design for This Report

Table 72. Key Data Information from Secondary Sources

Table 73. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Type: 2023 VS 2030

Figure 3. Oral Therapy Features

Figure 4. Injectable Therapy Features

Figure 5. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Application: 2023 VS 2030

Figure 7. Hospitals & Clinics Case Studies

Figure 8. Home Settings Case Studies

Figure 9. Ambulatory Surgical Centers (ASCs) Case Studies

Figure 10. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Report Years Considered

Figure 11. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 12. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Region: 2023 VS 2030

Figure 14. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Players in 2023

Figure 15. Global Top Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics as of 2023)

Figure 16. The Top 10 and 5 Players Market Share by Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in 2023

Figure 17. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 18. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Country (2019-2030)

Figure 19. United States Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. Canada Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Country (2019-2030)

Figure 23. Germany Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. France Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. U.K. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Italy Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Russia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Nordic Countries Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Region (2019-2030)

Figure 31. China Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Japan Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. South Korea Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Southeast Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. India Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Australia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Country (2019-2030)

Figure 39. Mexico Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Brazil Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Country (2019-2030)

Figure 43. Turkey Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Saudi Arabia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Astellas Inc. Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)

Figure 46. Johnson & Johnson Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)

Figure 47. Sanofi S.A Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)

Figure 48. Dendreon Corporation Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)

Figure 49. Bayer AG Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)

Figure 50. Bottom-up and Top-down Approaches for This Report

Figure 51. Data Triangulation

Figure 52. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions